Your partner in complex PCI: In-stent restenosis (ISR)
Your partner in complex PCI: In-stent restenosis (ISR)

Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety of the most complex coronary lesions types and morphologies, included in-stent restenosis.

Clinical Excellence

Customized offering, adapted to your needs

World-class healthcare

Procedural efficiency
Biologic causes
• Reaction to metal or polymer
• Drug resistance
• Thrombosis

Procedural causes
• Stent under-expansion/mal-apposition
• Stent fracture
• Edge trauma
• Geographical miss

ISR is >50% diameter stenosis at stent’s inside or edges, with different ISR morphologies predicting different TLR rates at 1-year.

Several factors with both biological and/or procedural causes contribute to the nature of ISR:

Incidence of ISR (meant PCI for DES restenosis) quite consistent over either National Registries, All-comers RCTs and Registries, in the range of ≈5%.

<table>
<thead>
<tr>
<th>Source</th>
<th>Design</th>
<th>Incidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassese et al.</td>
<td>Routine angiographic surveillance after unrestricted use of newer-generation devices</td>
<td>30.1% BMS, 14.6% 1st gen DES, 12.2% 2nd gen DES</td>
<td>Angio-binary restenosis</td>
</tr>
<tr>
<td>UK BCIS Audit</td>
<td>Registry of the British Cardiovascular Intervention Society</td>
<td>4.8%</td>
<td>PCI for restenosis, overall incidence (85% DES)</td>
</tr>
<tr>
<td>Spanish Registry</td>
<td>National Registry of Coronary and Structural Interventions (2010-2015)</td>
<td>4.7%</td>
<td>PCI for restenosis, could include DES, BMS, multi-layers</td>
</tr>
<tr>
<td>Norstent Study</td>
<td>Multicentric RCT 11 DES Vs. BMS</td>
<td>4.6%</td>
<td>PCI for DES restenosis</td>
</tr>
<tr>
<td>RESOLUTE All-Comers</td>
<td>Patients randomly assigned to R-ZES (n = 1,140) or EES (n = 1,152)</td>
<td>7.0% ZES, 6.5% EES</td>
<td>Clinically driven TLR</td>
</tr>
<tr>
<td>SCAAR Registry</td>
<td>SCAAR/SWEDHEART records consecutive patients from all centres (n=29) performing PCI in Sweden</td>
<td>5.6%</td>
<td>PCI treated in-stent restenoses</td>
</tr>
</tbody>
</table>

Malapposition (*) occurs at the junction of calcified and non-calcified plaque and in localized areas of reference segment ectasia at the stent edges. However, the stent is fully (albeit not symmetrically) expanded since the MSA of 6.0 mm² matches the proximal and distal reference segment lumen areas.
Physiology outperforms angiography in predicting functional significance of ISR, IVUS helps identify location and etiology of ISR to quickly determine and confirm best treatment options.
**Verrata Plus pressure guide wire**
Plan your procedure using iFR Co-Registration with SyncVision providing physiologic guidance, discriminating focal Vs. diffuse disease.

**Eagle Eye Platinum digital IVUS - Refinity ST rotational IVUS catheters**
With SyncVision with IVUS Co-Registration easily assess for geographic miss and edge complications, confirm stent apposition and optimal expansion for luminal gain.

**AngioSculpt PTCA Scoring Balloon**
Lesion preparation with AngioSculpt outperforms POBA for the treatment of DES-ISR with drug-coated balloons.¹¹

**ELCA coronary laser atherectomy**
Effective and safe plaque de-bulking for greater vessel and stent expansion.¹²

By modifying the plaque even behind the struts laser makes it more amenable to further stent expansion.¹²

**AngioSculptX drug-coated scoring balloon**
AngioSculptX is the first and only Treatment Solution combining Plaque Scoring and Drug Delivery in a Single Device¹³,¹⁴ for a safe and effective treatment of ISR.

---


©2018 Koninklijke Philips N.V. All rights reserved.
Some or all products manufactured by Spectranetics, a Philips company. Approved for external distribution. D046657-00 102018